rna
interfer
rnai
process
doublestrand
rna
dsrna
directli
degrad
correspond
target
mrna
scientif
commun
consid
rnai
breakthrough
biolog
discoveri
decad
potenti
chang
treatment
diseas
discoveri
gene
silenc
rnai
mammalian
system
facilit
use
rnai
therapeut
agent
cure
variou
ailment
mammalian
system
variou
effort
pipelin
creat
rnaibas
therapi
leverag
vast
potenti
technolog
treat
patient
fortun
till
date
great
success
achiev
util
power
potenti
rnai
therapeut
agent
clinic
trial
made
rapidli
approach
could
util
treatment
variou
noncur
lethal
human
diseas
thu
could
serv
gift
mankind
knockdown
gene
express
achiev
design
sirna
sequenc
exact
complementar
code
well
noncod
region
cellular
mrna
perfectli
induc
posttranscript
gene
silenc
ptg
target
organ
effector
molecul
rnai
phenomenon
long
sirna
duplex
chemic
synthes
variou
clinic
applic
vivo
implic
rnai
effector
molecul
must
uniformli
synthes
larg
scale
sirna
duplex
synthes
purpos
possess
overhang
end
synthet
sirna
amen
chemic
modif
increas
stabil
well
efficaci
natur
environ
sequenc
human
genom
provid
pace
develop
techniqu
implic
silico
methodolog
capabl
perform
background
task
sequenc
eas
effect
variou
commerci
entiti
avail
nowaday
make
use
algorithm
present
onlin
provid
research
effect
design
sirna
instantli
combin
mrna
target
sequenc
secondari
structur
sirna
duplex
end
stabil
design
effect
treatment
diseas
use
longer
dsrna
along
sirna
target
combin
increas
potenc
toward
ptg
asymmetr
design
one
overhang
one
blunt
end
sirna
produc
dice
dsrna
molecul
stringent
control
manner
dicer
recogn
overhang
process
blunt
end
possess
dna
base
capabl
induc
interferon
respons
minim
lower
concentr
requir
gene
silenc
signific
success
rnai
technolog
achiev
pioneer
work
carri
tuschl
et
al
abl
induc
silenc
cultur
mammalian
cell
introduct
dsrna
sirna
success
stori
research
identifi
basic
structur
sirna
capabl
induc
effici
silenc
gain
signific
sirna
thymidin
nucleotid
overhang
produc
costeffici
recent
develop
sirna
design
achiev
unfold
biochemistri
rnai
mechan
particularli
associ
sirna
rnainduc
silenc
complex
risc
reveal
antisens
strand
less
stabil
end
incorpor
enzymat
machineri
work
carri
reveal
structur
sirna
capabl
induc
effect
effici
gene
silenc
organ
particularli
caenorabd
elegan
rnadepend
rna
polymeras
amplifi
sirna
trigger
long
last
stabl
gene
silenc
rnadepend
rna
polymeras
absent
mammalian
cell
gene
silenc
induc
synthet
deliv
sirna
restrict
number
rna
molecul
introduc
cell
silenc
particular
gene
remain
effect
day
administr
sirna
cell
cultur
system
success
cell
divis
degrad
action
cellular
nucleas
dilut
sirna
count
time
nondivid
cell
like
macrophag
hepatocyt
cell
divid
slower
pace
gene
silenc
remain
effect
around
week
key
solut
problem
lie
synthesi
express
system
capabl
induc
uniform
univers
stabl
gene
silenc
produc
continu
suppli
sirna
group
scientist
synthes
shrna
short
hairpin
rna
express
vector
splice
factor
combat
problem
inconsist
express
rna
effector
molecul
mammalian
cell
sirna
induc
transient
effect
gene
silenc
shrna
mediat
longterm
stabl
knockdown
target
transcript
shrna
molecul
consist
dsrna
molecul
connect
short
loop
base
sequenc
base
present
loop
region
play
critic
role
effect
gene
silenc
dicer
form
sirna
ultim
process
shrna
depend
upon
type
express
requir
ie
transient
consist
differ
rna
polymeras
ii
rna
polymeras
iii
promot
use
accordingli
pol
iii
promot
consist
normal
cellular
function
produc
abund
endogen
small
cellular
rna
splice
rna
trna
transcript
initi
termin
signal
well
defin
highli
conserv
provid
advantag
uniform
express
almost
mammalian
cell
type
ie
divid
well
nondivid
besid
pol
iii
promot
shrna
express
cassett
exhibit
flexibl
express
larg
number
express
system
includ
virusbas
express
system
along
other
use
creat
transgen
anim
howev
lie
state
controversi
differ
promot
work
significantli
better
compar
other
particular
system
activ
silenc
molecul
enhanc
make
use
enhanc
element
promot
transcrib
long
transcript
cap
long
poli
tail
mimic
primirna
normal
transcrib
cell
primirna
precursor
molecul
either
transcrib
rna
pol
ii
independ
gene
repres
intron
proteincod
gene
long
transcript
transcrib
promot
effect
inhibit
target
gene
express
effici
incorpor
risc
express
pol
ii
promot
tissuespecif
similar
endogen
micro
rna
mirna
shrna
slightli
longer
base
pair
interact
effici
enzymat
machineri
lead
potent
gene
silenc
addit
advantag
use
pol
ii
promot
transcript
singl
promot
lead
simultan
synthesi
sever
mirna
mirna
origin
singlestrand
rna
ssrna
form
secondari
hairpin
structur
usual
exact
complementar
target
sequenc
contrast
sirna
origin
dsrna
exact
complementar
target
sequenc
nonselect
deliveri
approach
suitabl
tissu
like
liver
jejunum
specif
cell
system
deliveri
done
inject
sirna
conjug
cholesterol
rap
liposom
intraven
cholesterolconjug
group
shown
better
cellular
uptak
receptormedi
endocytosi
system
deliveri
apolipoprotein
b
apo
b
liver
jejunum
success
rate
reduct
apo
b
level
liver
reduct
jejunum
lower
overal
cholesterol
level
one
promis
outcom
gene
silenc
respons
observ
nonhuman
primat
transfect
sirna
conjug
stabl
nucleic
particl
snalp
snalp
consist
lipid
bilay
cation
neutral
lipid
outer
hydrophil
cover
polyethylen
glycol
peg
potent
silenc
effect
observ
cynomolgu
monkey
inject
singl
dose
snalpmedi
sirna
result
lower
apo
b
lowdens
lipoprotein
cholesterol
level
even
day
remnant
level
apo
b
mrna
liver
remark
toxic
sirnamedi
silenc
via
snalp
prove
effect
vivo
system
especi
therapeut
agent
express
liver
howev
consist
probabl
occurr
offtarget
effect
ote
due
nonspecif
sirna
deliveri
tissu
cell
type
repeat
administr
major
drawback
use
nonselect
deliveri
system
requir
larg
quantiti
sirna
gene
silenc
vivo
hand
select
deliveri
system
requir
low
dose
sirna
also
reduc
probabl
potenti
ote
nontarget
tissu
select
target
therapeut
sirna
coupl
antibodi
aptam
antibodi
link
sirna
use
treat
hivinfect
cell
sirna
link
antibodi
heavi
chain
fragment
possess
affin
envelop
glycoprotein
group
thu
specif
infect
cell
antibodi
heavi
chain
first
conjug
protamin
fuse
protein
use
deliv
sirna
hivinfect
cell
tag
fluoresc
label
induc
monitor
effect
specif
antibodymedi
sirna
deliveri
techniqu
addit
nanoparticl
also
frequent
use
specif
deliv
silenc
molecul
target
cell
nanoparticl
first
coat
receptor
specif
cell
type
target
therefor
taken
target
cell
present
nanoparticl
frequent
use
specif
sirna
deliveri
clinic
trial
due
stringent
specif
possess
chemic
modif
sirna
perform
overcom
two
basic
hurdl
one
increas
stabil
extracellular
well
intracellular
environ
effect
therapeut
molecul
applic
revers
genet
tool
sirna
unstabl
molecul
group
facilit
hydrolysi
acid
well
basic
environ
despit
cellular
nucleas
significantli
reduc
halflif
rna
vivo
purpos
reduc
ote
gain
desir
outcom
risc
machineri
specif
modifi
chemistri
sirna
function
stabil
enhanc
vivo
system
perman
cure
chronic
diseas
requir
stabl
well
longterm
rnai
express
effici
silenc
specif
target
gene
varieti
sirna
deliveri
vector
design
vivo
vitro
purpos
retroviralbas
shrna
vector
design
stabli
integr
shrna
transgen
primari
well
transform
cell
genom
integr
episom
express
capabl
express
hematopoiet
stem
cell
knockdown
tissu
mice
creat
use
vector
vital
concern
associ
viral
vector
use
gene
silenc
mechan
minim
toxic
effect
target
specif
cell
type
lentivir
vector
much
wider
applic
due
potenti
infect
noncycl
post
mitot
cell
neuron
rna
silenc
use
lentivir
vector
system
carri
silenc
specif
gene
primari
mammalian
cell
stem
cell
transgen
mice
infect
embryon
stem
cell
expect
function
ie
loss
particular
phenotyp
capabl
transmit
rnai
vector
futur
gener
enhanc
infect
rang
lentivir
vector
pseudotyp
number
envelop
protein
includ
vesicular
stomat
viru
g
glycoprotein
vsvg
carri
recent
lentivir
vector
use
deliv
shrna
express
cassett
hematopoiet
stem
cell
hivinfect
patient
ex
vivo
transfus
cell
reinfus
therapeut
heal
vivo
vector
creat
adenovirus
adenovirusassoci
virus
aav
capabl
infect
wide
rang
cell
type
vivo
virus
remain
isol
integr
host
genom
fact
case
found
capabl
induc
sever
immun
respons
howev
aav
capabl
caus
diseas
human
integr
defin
locat
genom
nullifi
probabl
gener
mutat
host
genom
site
integr
sirna
express
cassett
prefer
use
therapi
cancer
diseas
continu
rnai
express
requir
abl
transduc
divid
well
nondivid
cell
therapeut
shrna
gene
success
level
therapeut
approach
depend
upon
percentag
specif
possess
target
need
silenc
highli
target
approach
effici
use
therapeut
purpos
assist
extern
agent
requir
carri
neg
charg
doublestrand
sirna
across
hydrophob
cell
membran
liposom
nanoparticl
use
transport
sirna
inner
side
cell
also
protect
degrad
action
serum
rnase
snalp
aptam
antibodi
heavi
chain
fragment
also
use
deliveri
vehicl
differ
specif
nonspecif
viral
deliveri
method
shown
fig
system
deliveri
nanoparticl
contain
tumortarget
singl
chain
antibodi
fragment
result
signific
reduct
tumor
load
lung
rnai
wide
use
therapeut
tool
anim
model
mainli
rodent
cure
sever
neurodegen
diseas
majorli
includ
alzheim
diseas
amyotroph
later
sclerosi
al
huntington
diseas
hd
spinocerebellar
ataxia
success
demonstr
report
al
model
report
doubl
latenc
period
prolong
life
span
approxim
intramuscular
inject
shrna
rnai
effici
therapeut
tool
ocular
diseas
treatment
clinic
trial
primarili
carri
mous
model
substanti
output
clinic
trial
test
safeti
efficaci
techniqu
use
direct
intravitr
inject
sirna
target
vascular
endotheli
growth
factor
vegf
vascular
endotheli
growth
factor
aim
decreas
express
progress
decreas
express
vegf
result
suppress
abnorm
blood
vessel
develop
eye
patient
suffer
diabet
renopathi
amd
acuiti
pharmaceut
success
approach
estim
fact
posit
result
obtain
trial
carri
patient
worldwid
phase
level
http
wwwacuitypharmacom
sirna
therapeut
conduct
earli
stage
clinic
trial
obtain
posit
result
patient
till
date
http
wwwsirnacom
rnai
wide
use
develop
model
neurolog
disord
otherwis
difficult
gener
use
convent
transgen
approach
brainbas
studi
make
use
shrna
vector
deriv
aav
lentiviru
lv
rnai
therapi
facilit
longterm
uniform
suppress
gene
express
divid
well
nondivid
cell
synthet
rna
adenovir
system
herpessimplex
viral
system
use
vector
success
introduc
sirna
shrna
target
cell
aav
vector
system
design
way
express
shrna
target
leptin
receptor
protein
respons
control
feed
behavior
mice
leptin
hormon
respons
normal
food
intak
well
metabol
longterm
rnaimedi
knockdown
leptin
receptor
lepr
result
increas
food
intak
model
organ
shrna
introduc
dopamin
neuron
adult
mice
specif
knockingdown
th
gene
respons
encod
tyrosin
hydroxylas
th
gene
found
respons
parkinson
diseas
pd
knockdown
gene
result
decreas
motor
perform
well
known
central
nervou
system
cn
special
organ
human
bodi
almost
neglig
regener
abil
clinic
neurosci
therefor
aim
develop
effect
therapi
prevent
neuron
damag
caus
neurodegen
diseas
rnai
possess
enorm
potenti
treatment
genet
inherit
domin
neurodegen
diseas
root
caus
diseas
synthesi
inappropri
aggreg
deposit
sequestr
misloc
aberr
protein
hypothes
rnai
util
tool
synthesi
aberr
protein
henc
progress
neurodegen
diseas
hd
fatal
autosom
domin
neurodegen
disord
result
polyglutamin
repeat
expans
lead
cognit
behavior
disturb
chorea
neuron
inclus
striatal
cortic
neurodegener
ultim
lead
death
year
symptom
onset
till
date
occur
prevent
treatment
hd
potenti
rnai
explor
cure
domin
neurogen
diseas
reduct
mutant
gene
express
aav
system
use
shrnai
deliveri
signific
reduct
report
rna
silenc
direct
human
mhtt
mrna
protein
express
cell
cultur
hd
mous
brain
silenc
mhtt
gene
also
improv
behavior
well
neuropatholog
abnorm
associ
hd
intrastriat
raavmedi
deliveri
antihuntingtin
shrna
restrict
rnaimedi
partial
revers
diseas
progress
huntington
diseas
transgen
mice
associ
studi
reveal
use
lentivectormedi
rnai
develop
prion
diseas
therapi
prion
fatal
transmiss
neurodegen
diseas
pharmacolog
treatment
avail
three
etiolog
genet
lead
mutat
gene
encod
prion
protein
prp
acquir
due
exogen
prion
infect
sporad
unknown
caus
caus
prion
selfpropag
infecti
proteas
resist
form
prp
ie
prpsc
essenti
compon
identifi
till
date
prpsc
multipli
convers
normal
cellular
prp
prpc
clinic
manifest
symptom
model
organ
took
place
brain
got
serious
damag
therefor
diseasecur
therapi
mainli
aim
slow
diseas
progress
instead
aim
cure
host
cellular
prpc
requir
prion
replic
well
pathogenesi
host
organ
prion
replic
occur
mice
devoid
prpc
two
basic
therapeut
strategi
adopt
far
includ
reduct
prpc
level
prevent
convers
prpc
prpsc
lentivectormedi
rnai
significantli
reduc
neuron
prpc
express
effect
suppress
accumul
infecti
proteas
resist
form
prp
prpsc
persist
infect
neuroblastoma
cell
line
ultim
result
promin
reduct
progress
prion
diseas
uniqu
chimer
mice
model
rnai
manifest
viral
diseas
treatment
reli
upon
three
broad
strategi
one
way
target
host
gene
requir
viral
entri
propag
cell
cell
surfac
receptor
gene
one
util
viral
transcript
encod
essenti
viral
replic
protein
viral
infect
rnai
therapeut
potenti
target
viral
transcript
synthes
hivinfect
cell
mere
chang
singl
andor
two
amino
acid
suffici
creat
mismatch
pair
cleavag
site
sirna
greatli
reduc
potenc
rnai
viral
infect
rnai
specif
target
cellular
gene
elimin
major
problem
genet
variabl
occur
virus
hiv
infect
coreceptor
cc
chemokin
receptor
result
set
effici
promis
target
rnainduc
viral
therapi
homozyg
individu
base
pair
delet
ccr
gene
immun
hiv
infect
advers
immun
ailment
target
viral
genom
third
approach
use
highli
conserv
sequenc
present
viral
genom
act
promis
candid
therapeut
rnai
effect
use
rnai
viral
treatment
hivinfect
cultur
cell
experiment
demonstr
clinic
trial
rsv
hiv
track
make
rnaibas
strategi
effect
vivo
applic
variou
antivir
approach
use
treatment
includ
target
cell
host
individu
block
viral
integr
well
replic
process
gag
gene
encod
major
structur
protein
target
rnai
gene
therapeut
treatment
long
termin
repeat
ltr
accessori
protein
regulatori
protein
tat
rev
serv
effici
effect
target
studi
process
achiev
longterm
express
effector
futur
excel
great
success
primari
cell
obtain
tripl
rna
therapi
exploit
combinatori
use
tripl
rna
singl
short
hairpin
rna
rna
decoy
hiv
tar
element
surfac
viral
transcript
hammerhead
ribozym
lentivir
vector
use
clinic
trial
deliv
silenc
molecul
stem
cell
ex
vivo
hepat
b
viru
hbv
anoth
import
target
develop
rnaibas
therapeut
initi
viral
mrna
plasmid
express
shrna
pregenom
viral
rna
result
decreas
hbv
replic
express
two
viral
protein
chemic
modifi
synthet
sirna
encapsul
liposom
prevent
interferon
respons
stabil
longlast
effect
sirna
serum
anoth
studi
use
low
dose
aav
express
vector
shrna
result
inhibit
hbv
mous
model
consist
period
month
adenovir
vector
express
shrna
transgen
mous
model
reduc
hbv
gene
express
well
replic
establish
hbv
infect
studi
reveal
degre
stabil
effect
rnai
strategi
viral
infect
sirna
shrna
result
effect
block
infect
cultur
cell
either
target
hcv
genom
variou
viral
transcript
antivir
rnai
strategi
target
negativerna
strand
viru
rsv
majorli
affect
children
elder
person
intranas
administr
sirna
use
nanoparticl
effect
elicit
rnai
show
reduct
viral
titr
lung
time
viral
infect
without
induc
interferon
respons
decreas
inflamm
mice
howev
postinfect
administr
rnai
effector
show
minim
activ
infect
sirnabas
clinic
trial
use
rsv
deliveri
agent
gain
fast
access
effect
approach
addit
rnaibas
therapeut
also
develop
ebola
viru
herp
simplex
sar
coronaviru
infect
mice
block
vagin
applic
lipidencapsul
sirna
target
hsv
gene
day
infect
mice
treat
singl
type
sirna
infect
show
complet
resist
infect
howev
combin
two
sirna
differ
target
requir
appli
postinfect
prevent
diseas
result
show
effect
lipidencapsul
sirna
microbicid
mucos
surfac
appar
toxic
vivo
internas
deliveri
studi
mucos
surfac
serv
effici
site
sirna
deliveri
regard
access
well
cost
effect
matter
target
import
consider
util
rnai
antivir
approach
sequenc
specif
viral
genom
possess
inher
abil
get
frequent
mutat
possess
signific
hurdl
use
antivir
rnai
therapeut
mutat
lead
develop
viral
resist
exampl
continu
cultur
cell
line
express
shrna
lead
sequenc
alter
addit
delet
make
ineffect
viru
use
vector
capabl
express
multipl
shrna
target
independ
sequenc
may
help
overcom
potenti
hurdl
rnai
resist
mutat
owe
high
specif
potenc
low
toxic
sirna
use
altern
strategi
compar
convent
anticanc
drug
overcom
lifethreaten
condit
caus
tumor
advanc
develop
deliveri
agent
silenc
molecul
provid
advantag
specif
target
oncogen
thu
act
signific
therapeut
agent
cancer
therapi
system
deliveri
also
proven
effect
treatment
metastat
tumor
barrier
hinder
path
sirna
target
cell
effect
oncogen
silenc
well
lung
metastasi
inhibit
achiev
system
deliveri
sirna
mice
model
use
nanoparticl
shown
fig
nanoparticl
synthes
selfassembl
method
possess
sirna
calf
thymu
dna
carrier
dna
protamin
polycation
peptid
coat
within
cation
lipid
surfac
modifi
pegconjug
ligand
anisamid
specif
target
sigma
receptorexpress
cell
use
ligand
improv
effici
deliveri
sirna
fourfold
metastat
tumor
compar
nonligandco
nanoparticl
calf
dna
provid
less
immunotox
compar
plasmid
vector
due
presenc
lesser
amount
cpg
motif
sequenc
combin
three
sirna
sequenc
use
attack
multipl
oncogen
pathway
simultan
gain
synergist
antiprolifer
cell
inactiv
cmyc
transcript
factor
promot
cell
prolifer
vegf
mediat
angiogenesi
metastasi
use
weight
ratio
result
synergist
antiprolifer
effect
metastat
nodul
mice
model
draft
xenograft
tumor
tissu
murin
melanoma
cell
also
transduc
luciferas
gene
analyz
efficaci
silenc
even
singl
intraven
iv
inject
mgkg
antiluciferas
sirna
metastat
nodul
result
reduct
luciferas
activ
preliminari
data
also
reveal
potenti
effici
achiev
tumor
therapi
target
nanoparticl
formul
first
clinic
trial
sirna
human
carri
patient
suffer
cnv
choroid
neovascular
clinic
trial
diseas
make
use
sirna
therapeut
molecul
gain
speed
clinic
data
therefor
start
accumul
variou
disord
first
clinic
trial
sirna
therapeut
molecul
carri
human
use
nanoparticledeliveri
system
clinic
trial
registr
number
patient
suffer
solid
cancer
mechan
action
rnai
human
manifest
tumor
biopsi
myeloma
patient
carri
nanoparticl
deliveri
although
nanoparticl
deliv
system
bodi
clear
indic
intracellular
local
nanoparticl
establish
correl
dose
nanoparticl
inject
present
tumor
compar
analysi
predos
tissu
show
reduct
level
specif
messeng
rna
subunit
ribonucleotid
reductas
protein
moreov
rnai
mechan
valid
mrna
fragment
detect
predict
site
patient
inject
highest
dose
nanoparticl
confer
system
administ
sirna
capabl
specif
gene
inhibit
rnai
aim
scientist
work
modern
drug
research
develop
discov
biolog
activ
molecul
class
biolog
activ
molecul
function
specif
potenti
act
effici
etiolog
target
diseas
larg
varieti
drug
use
diseas
treatment
present
time
interact
kind
protein
found
critic
innat
function
certain
cell
tissu
organ
matter
concern
problem
nontarget
protein
target
along
target
protein
bodi
side
effect
convent
therapi
may
result
unknown
interact
protein
total
knockdown
multidomain
protein
carri
truncat
particular
domain
would
ultim
lead
alter
structur
whole
protein
ultim
alter
function
complement
consid
exampl
major
class
drug
use
cure
diabet
thiazolidinedion
tzd
tzd
improv
insulin
sensit
present
islet
langerhan
drug
also
suppos
bind
peroxisom
proliferatoractiv
key
adipogen
transcript
factor
white
adipos
tissu
addit
lead
activ
gene
concern
glucos
lipid
metabol
like
adiponectin
advers
effect
administr
insulin
drug
includ
renal
liver
toxic
suppos
occur
due
indiscrimin
nonspecif
activ
system
kidney
well
liver
tissu
progress
function
genom
open
knot
variou
fundament
molecular
mechan
underli
regulatori
process
gene
express
well
dysfunct
ribonucl
acid
respons
code
protein
compliment
cell
ideal
target
diseas
treatment
drug
discoveri
import
mediat
gene
express
effici
way
silenc
express
defect
gene
rna
level
achiev
synthes
complementari
sequenc
ssrna
sequenc
complementari
base
pair
sequenc
lead
function
disrupt
futur
defect
protein
encod
rna
sequenc
import
potenti
advantag
use
rnai
lie
target
specif
inher
mechan
sequencebas
gene
suppress
design
therapeut
two
interconnect
aspect
almost
gene
neither
function
gene
product
inform
protein
structur
mandatorili
requir
knock
particular
gene
effici
effect
therefor
scenario
rnai
therapeut
tool
expand
day
day
cure
certain
incur
fatal
diseas
particular
defect
gene
select
inhibit
especi
case
diseas
often
caus
domin
mutat
singl
allel
like
agerel
macular
degener
amd
diabet
retinopathi
respiratori
syncyti
viru
rsv
detail
mechan
rnai
illustr
fig
sever
studi
carri
determin
efficaci
rnai
comparison
therapeut
approach
like
antisens
technolog
conclud
rnaimedi
inhibit
prove
potent
contrast
case
site
select
optim
antisens
effect
also
reflect
remark
pace
rnai
techniqu
implement
scientif
research
well
therapeut
tool
accord
number
success
rnaibas
experi
alreadi
publish
advent
rapid
progress
field
rnai
technolog
own
innat
biolog
abil
gene
silenc
henc
repres
natur
strategi
manipul
gene
express
total
block
microarray
studi
reveal
sirna
capabl
silenc
mani
unintend
transcript
along
target
one
offtarget
gene
silenc
discov
hurdl
vivo
gene
silenc
mechan
use
sirna
accept
complic
rnai
therapi
lead
develop
undesir
phenotyp
offtarget
transcript
silenc
affect
specif
sirna
clinic
purpos
even
singl
nucleotid
mismatch
capabl
reduc
potenc
target
gene
silenc
minim
ote
local
align
algorithm
blast
smithwaterman
use
use
align
sequenc
share
signific
level
ident
eg
bp
gene
target
genom
diagnos
sequenc
avoid
synthes
sirna
sequenc
inhibit
function
desir
gene
small
section
experiment
valid
offtarget
identifi
silico
method
suggest
even
overal
sequenc
ident
act
poor
forecast
number
ident
offtarget
gene
fail
sequenc
align
tool
toward
escap
ote
led
rnai
user
devic
altern
reduc
effect
ie
reduc
sirna
concentr
chemic
modifi
sirna
appli
challeng
bioinformat
sirna
design
offtarget
gene
silenc
concentr
depend
decreas
concentr
sirna
ote
also
fade
unintend
silenc
result
complementari
sequenc
present
utr
nontarget
transcript
seed
hexam
string
sirna
possess
sequenc
complementari
utr
nontarget
transcript
thu
complementari
base
pair
region
result
offtarget
gene
silenc
seedmatch
offtarget
silenc
hereaft
refer
micrornalik
silenc
resembl
mirnainduc
gene
silenc
procedur
howev
complementari
base
pair
occur
guid
seed
strand
sequenc
open
read
frame
orf
unintend
transcript
ote
report
region
modifi
use
facil
variou
utr
search
algorithm
present
onlin
minim
detriment
ote
genomewid
librari
use
design
rnai
reagent
improv
knockdown
effici
simultan
minim
ote
potenti
reduct
ote
achiev
modif
seed
region
sirna
sens
strand
modifi
manner
prevent
interact
risc
therefor
favor
antisens
strand
uptak
contrast
antisens
strand
seed
region
modifi
minim
seed
relat
offtarget
strategi
reduc
ote
maintain
potenc
rnai
mechan
positionspecif
chemic
modif
sirna
duplex
reveal
silenc
offtarget
transcript
sirna
reduc
without
halt
silenc
intend
target
blast
search
done
within
genom
find
sequenc
homolog
rnai
sequenc
sirna
design
minim
ote
escap
sequenc
homolog
approach
experiment
valid
plant
syn
gene
complement
gene
synthes
code
ident
protein
code
target
nat
gene
complement
silenc
phenotyp
syn
gene
variant
also
design
suffici
differ
nucleotid
sequenc
nat
gene
escap
rnaiinduc
silenc
phenotyp
found
complet
revers
express
syn
gene
sirna
use
therapeut
molecul
must
design
stringenc
toward
intend
target
gene
neglig
activ
toward
unintend
gene
prior
develop
rnaibas
therapi
preclin
studi
relat
cellular
function
viabil
approach
must
assess
analyz
success
rate
key
solut
convent
monotherapi
consist
problem
viral
evolut
resolv
artifici
synthes
singlestrand
sirna
molecul
simultan
knock
express
multipl
target
novel
approach
well
known
combinatori
rnai
cornai
multiplex
strategi
great
signific
therapeut
abil
block
gene
express
two
therapeut
target
simultan
well
also
target
sever
site
singl
gene
product
ie
mrna
silenc
singl
gene
routin
practic
limit
number
studi
report
concurr
silenc
one
gene
use
combin
sirna
major
combinatori
rnai
studi
focus
silenc
two
target
simultan
sirna
librari
prepar
gene
whose
effect
need
silenc
synthet
sirna
prepar
valid
activ
carri
molecular
level
use
approach
practic
term
librari
compris
randomli
gener
multiplex
creat
streamlin
cell
system
use
approach
effect
coadminist
sirna
studi
dissect
role
rab
protein
ie
rab
protein
cooper
regul
dock
step
densecor
vesicl
exocytosi
cell
effect
sirna
coadministr
usual
character
phenotyp
level
therefor
experiment
multiplex
consist
six
sirna
carri
valid
condit
simultan
silenc
multipl
target
breast
cancer
cell
line
gener
sirna
librari
six
sirna
direct
three
uniqu
gene
target
silenc
gene
multiplex
sirna
found
effect
silenc
achiev
individu
sirna
similar
result
also
observ
multiplex
twelv
sirna
six
gene
target
consist
problem
viral
evolut
also
resolv
use
cornai
phenomenon
use
multipl
conserv
sequenc
viral
genom
enhanc
chanc
escap
mutant
cornai
approach
first
use
studi
gene
function
use
two
shrna
target
glycogen
synthas
kinas
via
simultan
inhibit
multipl
endogen
mrna
function
gene
studi
use
cornai
approach
includ
cotarget
multipl
sod
gene
cyclin
sphase
kinaseassoci
protein
relat
kinas
braf
craf
power
sirna
cosuppress
use
bispecif
lv
vector
reveal
target
hivinfect
cell
regul
cell
receptor
primari
receptor
coreceptor
monocytemacrophagetrop
hiv
along
cell
tropic
hiv
coreceptor
result
prevent
hiv
infect
sirna
construct
engin
transfect
hivpermiss
cell
includ
peripher
blood
mononuclear
cell
viru
challeng
assay
show
strike
protect
transfect
cell
hiv
clinic
applic
bispecif
sirna
doubt
may
result
evok
ifn
respons
valid
abil
multiplex
sirna
coregul
sever
gene
sirnamedi
rnai
offer
robust
potenti
studi
interact
biomolecul
variou
biolog
pathway
analysi
could
princip
appreci
develop
drug
promot
identif
molecular
target
combin
creat
predominantli
lethal
phenotyp
addit
offer
novel
therapeut
applic
rnai
possess
limit
obviat
limit
convent
gene
therapi
deliveri
sirna
target
tissu
major
problem
face
exploit
nativ
mechan
rnai
clinic
therapi
cure
diseas
new
target
method
develop
improv
transfect
effici
carrier
system
synthet
sirna
inject
host
cell
also
need
protect
rapid
degrad
action
cellular
nucleas
earlier
tremend
growth
reveal
factor
concern
rnai
mechan
understand
rnai
biolog
allow
nucleotid
modif
facilit
load
guid
strand
risc
improv
sirna
sequenc
select
also
improv
effici
rnai
nevertheless
problem
readministr
persist
due
temporari
cure
diseas
intracellular
dilut
sirna
occur
cell
divis
bind
nonspecif
target
may
elicit
unpredict
unwant
side
effect
matter
signific
concern
endogen
splice
machineri
target
cell
block
harm
due
competit
bind
sirna
sequenc
endogen
mirna
pathway
compon
inspit
limit
major
problem
also
capabl
elicit
interferon
immun
respons
host
bodi
convent
gene
therapeut
strategi
focus
vastli
gene
replac
affect
gene
target
host
cell
howev
progress
gene
therapi
slow
move
basic
research
clinic
approach
challeng
aris
heterolog
dna
deliveri
gene
regul
vivo
system
therefor
limit
potenti
gene
therapi
practic
use
altern
approach
target
rna
rather
dna
possess
abil
overcom
difficulti
concern
tradit
gene
therapi
activ
therapeut
molecul
use
altern
approach
majorli
compris
short
oligonucleotid
sequenc
rnai
recent
emerg
power
altern
convent
gene
replac
therapi
correct
genet
defect
mainli
concern
correct
autosom
domin
diseas
low
effici
gene
transfer
limit
transgen
size
specif
inabl
deliv
genom
size
loci
insert
mutagenesi
integrationassoci
event
immun
respons
toxic
also
limit
convent
gene
therapi
novel
therapeut
applic
use
rnai
includ
alter
process
target
premrna
transcript
reprogram
genet
diseas
mrna
repair
mechan
along
target
silenc
allel
isoformspecif
gene
transcript
realiz
potenti
rnaibas
therapeut
approach
address
genet
disord
still
need
reveal
fulli
signific
discoveri
rnai
andrew
fire
craig
mello
award
nobel
prize
medicin
physiolog
year
innat
principl
gene
regul
util
develop
therapeut
agent
rnaibas
therapi
cure
variou
fatal
diseas
trial
gain
remark
success
trial
model
organ
enorm
unpreced
therapeut
potenti
rnai
encount
hurdl
like
interferon
respons
ote
excess
dosag
promoterbas
shrna
even
lead
death
inject
model
organ
sinc
decad
ago
rnai
emerg
promis
power
experiment
tool
novel
therapeut
rnai
wide
explor
attent
domin
target
involv
ocular
neurodegen
hd
therapeut
howev
still
imper
comprehend
present
knowledg
biolog
function
rnai
mechan
perhap
repres
tip
iceberg
great
deal
technic
issu
challeng
need
overcom
henc
unearth
novel
featur
rnairel
process
import
continu
futur
studi
anim
model
parallel
research
mammalian
cell
cultur
system
hope
addon
progress
highli
effici
rnaibas
therapi
